NASDAQ:COGT Cogent Biosciences (COGT) Stock Price, News & Analysis $16.02 +0.26 (+1.62%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cogent Biosciences Stock (NASDAQ:COGT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cogent Biosciences alerts:Sign Up Key Stats Today's Range$15.73▼$16.1650-Day Range$10.86▼$15.7652-Week Range$3.72▼$16.16Volume135,615 shsAverage Volume1.93 million shsMarket Capitalization$1.82 billionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingModerate Buy Company Overview Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments. The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors. Preclinical studies have demonstrated the candidate’s ability to deplete immunosuppressive macrophages within the tumor microenvironment, resulting in antitumor activity as a monotherapy and in combination with checkpoint inhibitors. Cogent continues to explore additional novel small molecules that can influence immune-regulatory pathways in oncology. Founded in 2016 and headquartered in Cambridge, Massachusetts, Cogent Biosciences completed its initial public offering in 2020 and maintains operations in key U.S. research hubs. The company leverages collaborative partnerships with academic institutions and contract research organizations to advance its pipeline efficiently. While most of its clinical programs are currently being evaluated in North America, Cogent is positioned to pursue international trial sites as it progresses through later-stage development. Under the leadership of President and Chief Executive Officer Daniel Welch, Cogent Biosciences is guided by a management team with deep experience in oncology drug development, translational research, and regulatory strategy. The company’s board and scientific advisory committees include experts in immuno-oncology and precision medicine, supporting its mission to bring novel targeted therapies to patients with unmet medical needs.AI Generated. May Contain Errors. Read More Cogent Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreCOGT MarketRank™: Cogent Biosciences scored higher than 53% of companies evaluated by MarketBeat, and ranked 571st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialCogent Biosciences has a consensus price target of $20.00, representing about 26.9% upside from its current price of $15.76.Amount of Analyst CoverageCogent Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cogent Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($2.42) to ($2.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -8.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -8.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 11.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cogent Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.21% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 15.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.21% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 15.10%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.56 News SentimentCogent Biosciences has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cogent Biosciences this week, compared to 4 articles on an average week.Search Interest9 people have searched for COGT on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,999,993.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.29% of the stock of Cogent Biosciences is held by insiders.Read more about Cogent Biosciences' insider trading history. Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COGT Stock News HeadlinesCogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 29, 2025 | globenewswire.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives $20.00 Consensus PT from BrokeragesSeptember 26, 2025 | americanbankingnews.comAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says the real opportunity is in a little-known strategy that has historically outpaced gold’s rallies many times over — including one past run where investors saw gains of more than 26,000%.October 6 at 2:00 AM | Weiss Ratings (Ad)Cogent Biosciences added to Analyst Current Favorites list at Raymond JamesSeptember 16, 2025 | msn.comOne Cogent Biosciences Insider Raised Stake By 2,085% In Previous YearSeptember 12, 2025 | finance.yahoo.comRaymond James Initiates Coverage of Cogent Biosciences (COGT) with Strong Buy RecommendationSeptember 4, 2025 | msn.comCogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comCogent Biosciences: Moving ForwardAugust 26, 2025 | seekingalpha.comSee More Headlines COGT Stock Analysis - Frequently Asked Questions How have COGT shares performed this year? Cogent Biosciences' stock was trading at $7.80 at the beginning of the year. Since then, COGT shares have increased by 102.1% and is now trading at $15.76. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) announced its quarterly earnings results on Tuesday, August, 5th. The technology company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.02. How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Visa (V), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/05/2025Today10/05/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COGT CIK1622229 Webwww.cogint.com Phone(617) 945-5576FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for Cogent Biosciences$20.00 High Price Target$30.00 Low Price Target$9.00 Potential Upside/Downside+26.9%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$255.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-223.82% Return on Assets-89.44% Debt Debt-to-Equity RatioN/A Current Ratio4.19 Quick Ratio4.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book11.94Miscellaneous Outstanding Shares113,860,000Free Float105,556,000Market Cap$1.79 billion OptionableOptionable Beta0.30 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:COGT) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.